CD55 and ganglioneuroma: Cantaluppi et al. demonstrated that EVs derived from EPCs carry complement inhibitors such as factor H, decay-accelerating factor (DAF/CD55) and CD59 and can blunt antibody- and complement-mediated injury (reduced intra-glomerular deposition of membrane attack complex) in Thy1.1 GN, a model of mesangial proliferative GN characterized by EC and mesangial cell loss followed by mesangial proliferation [46,79].